Inicio › Leucemia bifenotípica aguda › Oklahoma

Ensayos clínicos de Leucemia bifenotípica aguda en Oklahoma

5 estudios sobre Leucemia bifenotípica aguda buscan participantes en Oklahoma.

Ciudades en Oklahoma

Texto oficial del estudio (inglés)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

University of Oklahoma Health Sciences Center, Oklahoma City

ReclutandoFase 2

365 Days · Todos los sexos · Actualizado el 25 sept 2026 · NCT06317662

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

University of Oklahoma Health Sciences Center, Oklahoma City

ReclutandoFase 1/2

Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

University of Oklahoma Health Sciences Center, Oklahoma City
Saint Francis Children's Hospital, Tulsa

ReclutandoFase 3

365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Saint Francis Children's Hospital, Tulsa

ReclutandoFase 2

Edades de 1 a 18 · Todos los sexos · Actualizado el 10 ago 2026 · NCT06390319

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Saint Francis Children's Hospital, Tulsa

ReclutandoFase 4

Edades de 1 a 18 · Todos los sexos · Actualizado el 14 jul 2026 · NCT06289673

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.